American Cancer Society

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Retrieved on: 
星期三, 三月 13, 2024
Health, Oncology, Clinical Trials, Medical Supplies, Harvard Medical School, Colonoscopy, Colorectal cancer, Helmy Eltoukhy, Survival rate, Massachusetts General Hospital, Cancer, Risk, Patient, Ageing, Evaluation, American Cancer Society, Neoplasm, Perception, DNA, MD, Circulating tumor DNA, Hospital, PMA, CRC, Large intestine, Multimedia, FDA, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240313547689/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240313547689/en/
    Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk.
  • (Photo: Business Wire)
    “Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,” said AmirAli Talasaz, Guardant Health co-CEO.
  • The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).
  • One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield.

The Canadian Cancer Society is calling for a united show of support for those affected by cancer and to help hope bloom this April

Retrieved on: 
星期二, 四月 2, 2024
Diagnosis, Health, Survival rate, Disease, American Cancer Society, Research, Cancer, Hope, Death, CCS, Love, Pharmaceutical industry

April's Daffodil Month unites people to fund world-leading cancer research and support programs that are saving and improving lives.

Key Points: 
  • April's Daffodil Month unites people to fund world-leading cancer research and support programs that are saving and improving lives.
  • A Canadian tradition for more than 65 years, the Canadian Cancer Society's Daffodil Month has a rich legacy of changing the future of cancer.
  • Progress is possible when we act together," says Andrea Seale, Chief Executive Officer of the Canadian Cancer Society.
  • This Daffodil Month, CCS is inviting people across Canada to join us to help hope bloom for those affected by cancer by visiting cancer.ca/daffodil to:

Workflow Services Partners with Exact Sciences to Provide Colorectal Cancer Screening for Patients with Access Challenges at the Pharmacy

Retrieved on: 
星期五, 三月 29, 2024
Biotechnology, EVP, Colorectal cancer, Partnership, Cancer, Patient, Pharmacy, American Cancer Society, Exact sciences, Pharmacist, Death, Risk, Exact Sciences (company)

MADISON, Wis., March 29, 2024 /PRNewswire/ -- Workflow Services, an automated platform that solves point-of-care clinical service delivery for pharmacies, announced a new agreement with Exact Sciences, a biotechnology company that develops tests designed to prevent, detect, and guide the successful treatment of cancer. This new partnership brings the power of the Workflow Services platform—a full spectrum, front-to-back digital solution supporting point-of-care service delivery—to help educate eligible patients who visit the pharmacy on the importance of having a colorectal cancer screening.  

Key Points: 
  • This new partnership brings the power of the Workflow Services platform—a full spectrum, front-to-back digital solution supporting point-of-care service delivery—to help educate eligible patients who visit the pharmacy on the importance of having a colorectal cancer screening.
  • When detected at an early stage, colorectal cancer, the second leading cause of death from cancer in the U.S., is highly treatable in about 90% of cases*.
  • In this new approach, pharmacists are empowered to use the Workflow Services platform to educate patients about colorectal cancer screening options.
  • To learn more about colorectal cancer screening, visit Exact Sciences .

Ambetter from Sunshine Health and Tampa Bay Buccaneers Tackle Colorectal Cancer During Colorectal Cancer Awareness Month

Retrieved on: 
星期二, 三月 26, 2024
Health, Colonoscopy, Colorectal cancer, Disease, Partnership, Risk, American Cancer Society, African Americans, Football, Research, Death, Bucs, CNC, Woman, Super, Buccaneer, Super Bowl, Large intestine, Centene Corporation, PSA, Tampa Bay Buccaneers

TAMPA, Fla., March 26, 2024 /PRNewswire/ -- As Colorectal Cancer Awareness Month continues throughout March, Ambetter from Sunshine Health and the Tampa Bay Buccaneers are teaming up to spread awareness about colorectal cancer by unveiling a powerful public service announcement (PSA). The video featuring Shelton Quarles, Buccaneers Director of Football Operations and former Super Bowl-winning linebacker for the team, is aimed at raising awareness about the importance of preventive screenings.

Key Points: 
  • TAMPA, Fla., March 26, 2024 /PRNewswire/ -- As Colorectal Cancer Awareness Month continues throughout March, Ambetter from Sunshine Health and the Tampa Bay Buccaneers are teaming up to spread awareness about colorectal cancer by unveiling a powerful public service announcement (PSA).
  • Through this joint effort, Ambetter from Sunshine Health and the Buccaneers are committed to sharing vital health information that has the potential to make a profound impact in the fight against colorectal cancer.
  • Colorectal cancer is the second most common cause of cancer deaths in the United States in both men and women.
  • Additionally, colorectal cancer disproportionately affects Black Americans , who are 20% more likely to get colorectal cancer and about 40% more likely to die from it than other groups.

Promising New Data Published on Potential Therapy to Boost Effectiveness of Pancreatic Cancer Treatments

Retrieved on: 
星期二, 三月 26, 2024
Toxicity, Cell, Development, Survival, BLR, Disease, American Cancer Society, PNAC, Research, University, Quality of life, Cancer, IND, Pharmacology, Pancreatic cancer, Mario, Potential, RFU, Therapy, Helix, Person, Pharmaceutical industry

The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers.

Key Points: 
  • The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers.
  • According to the American Cancer Society , some 66,000 persons in the U.S. are diagnosed annually with pancreatic cancer, a disease with a very low survival rate that is projected to take 51,000 lives in 2024.
  • "Finding an approach to use lower doses while maintaining efficacy has been a constant search for cancer treatments."
  • "BLR-100 targets the formation of the protective tumor stroma, a fibrotic-like element that is thought to retard the entry of chemo-therapeutic agents."

Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029

Retrieved on: 
星期四, 三月 21, 2024
Diagnosis, University, Qiagen, Breast cancer, PerkinElmer, Lung cancer, Medical device, Research, Government, Burn, Drug discovery, Health, Pressure, Growth, Prevalence, Organization, Learning, Figure, Prostate cancer, The BMJ, Tufts University, Incidence, Thermo Fisher Scientific, COVID-19, Danaher Corporation, Conditional sentence, American Cancer Society, RNA, DNA, Female, Robotics, Cancer, Software, Wyss Institute, Laboratory, Woman, Regenerative medicine, Harvard University, Drug development, Xenobot, Medical journal, Pharmaceutical industry

DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.
  • The molecular robotics market is expected to witness a CAGR of 18% over the forecast period.
  • Active participation of universities in drug research and molecular robotics is also supporting the growth of the studied market.
  • Most of the players focus on bringing technologically advanced products into the market to acquire the maximum market share.

Federal announcement to restrict marketing and sales of nicotine pouches a needed move to protect youth

Retrieved on: 
星期四, 三月 21, 2024
Canadian Cancer Society, Minor, Imperial Brands, Tobacco industry, Herbal cigarette, American Cancer Society, Federation, Risk, Pharmacy, Social media, Candy, Sale, Imperial Tobacco Canada, Smoking, Nicotine, Marketing, Advertising, Tobacco

At present, in most provinces, nicotine pouches can be sold in any store, including convenience stores and gas stations.

Key Points: 
  • At present, in most provinces, nicotine pouches can be sold in any store, including convenience stores and gas stations.
  • "Federal restrictions on the sale and marketing of nicotine pouches will help prevent nicotine addiction among youth and protect them from tobacco industry marketing strategies," says Rob Cunningham, Senior Policy Analyst, Canadian Cancer Society.
  • Yesterday's announcement comes weeks after British Columbia in February restricted the sale of nicotine pouches in the province to behind the counter in pharmacies.
  • With flavored nicotine pouches hitting the market last year, there's a renewed risk of young people becoming addicted to these new tobacco industry products.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
星期四, 三月 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
星期四, 三月 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Bemis Donates Toilet Seats for Cancer Advocacy Event in Washington, D.C.

Retrieved on: 
星期三, 三月 13, 2024
Mall, Colorectal cancer, Congress, Partnership, American Cancer Society, Research, Death, Woman, Bemis Manufacturing Company, CRC, Breast cancer, ACS, Large intestine, Marketing, National Mall

SHEBOYGAN FALLS, Wis., March 12, 2024 /PRNewswire/ -- Bemis Manufacturing Company, a leading manufacturer of toilet and bidet seats, announced its continued partnership with Fight Colorectal Cancer (Fight CRC) for Colorectal Cancer Awareness Month. For the third year in a row, Bemis has donated 100 toilet seats to support Fight CRC's Call-on Congress event in Washington, D.C.

Key Points: 
  • SHEBOYGAN FALLS, Wis., March 12, 2024 /PRNewswire/ -- Bemis Manufacturing Company, a leading manufacturer of toilet and bidet seats, announced its continued partnership with Fight Colorectal Cancer (Fight CRC) for Colorectal Cancer Awareness Month.
  • For the third year in a row, Bemis has donated 100 toilet seats to support Fight CRC's Call-on Congress event in Washington, D.C.
  • The donated toilet seats are displayed on the National Mall as part of Fight CRC's advocacy efforts.
  • Each seat features an awareness fact or statistic about colorectal cancer, the second-deadliest cancer in the United States among men and women combined.